Chapter
Chapter 1: Opioid modulation of cognitive impairment in depression
2. Opioid Ligands and Cognitive Function: Clinical Evidence
3. Opioid Ligands and Cognitive Function: Preclinical Evidence
4. Opioids, Cognition, and Aging
5. Potential Opioid Mechanisms of Cognitive and Motivational Deficits
Chapter 2: Modulation of the central opioid system as an antidepressant target in rodent models
1.1. Experimental Approaches
2. Neuroanatomical and Neurochemical Associations Between the Central Opioid and Monoamine Systems
3. Modulating the Endogenous Central Opioid Receptor System in Rodent Models of Depression
3.1. The Mu Opioid Receptors
3.2. The Kappa Opioid Receptor
3.3. The Delta Opioid Receptor
3.3.1. Indirectly Acting DOP Agonists
3.3.2. Directly Acting DOP Agonists
4. The Nociceptin/Orphanin FQ Receptor
5. Targeting More Than One Opioid Receptor
6. Opioid Contributions to the Mechanisms of Currently Marketed Antidepressants
7. Clinical Evaluations of Opioid-Modulating Drugs
Chapter 3: Potential roles for opioid receptors in motivation and major depressive disorder
1.1. Opioids and Motivation
3. Opioids and Motivational Behavior in Depression
4. Animal Models of Depression and Motivation
4.1. Animal Model of Motivational Dysfunction
4.2. Opioids in Reward/Motivation Behavior in Animal Models of Depression
5. Underlying Neurocircuity: Brain Systems and Neural Signaling Mechanisms
5.2. Opioid and Dopaminergic Signaling Contributions to Motivational Behavior
5.3. Opioids and Dopamine Regulation
5.4. Opioid Intracellular Signaling
6. Drug-Induced Changes in Motivational Behavior
Chapter 4: Stress-induced modulation of pain: Role of the endogenous opioid system
2. Impact of Stress on Pain
3. The Endogenous Opioid System
4. Opioid System and Pain
5. Role of Endogenous Opioid System in SIA
5.1.1. Pharmacological studies
5.1.1.1. Mu opioid receptor
5.1.1.2. Kappa opioid receptor
5.1.1.3. Delta opioid receptor
5.1.1.4. Nociceptin/orphanin FQ receptor
6. Role of Endogenous Opioid System in SIH
6.1.1. Pharmacological studies
6.1.1.1. Mu opioid receptor
6.1.1.2. Kappa opioid receptor
6.1.1.3. Delta opioid receptor
6.1.1.4. Nociceptin/orphanin FQ receptor
7. Conclusions and Future Directions
Chapter 5: Frontal cortex dysfunction as a target for remediation in opiate use disorder: Role in cognitive dysfunction a ...
2. The Corticostriatal Circuit: Important Cell Types and Circuit Organization
2.1.1. Frontal cortex microcircuitry: General organization
2.1.2. Frontal cortex: Important cell types
2.1.2.1. Pyramidal neurons
2.1.2.2. Parvalbumin-immunoreactive (PVIR) interneurons
2.1.2.3. Non-PVIR interneurons
2.2.1. Striatal microcircuitry: Organization
2.2.2. Striatal microcircuitry: Important cell types
2.2.2.1. Medium spiny neuron (MSN)
2.2.2.2. PVIR interneurons
2.3. Relationships Between Frontal Cortex and Striatal Microcircuitry
3. The Corticostriatal Circuit: Relevance for Cognitive Function and Reward Signaling
3.1. A Role for the Frontal Cortex in Cognitive Function
3.2. A Role for the Corticostriatal Circuit in Reward
3.2.1. NAc reward circuitry: It's not all about dopamine
3.2.2. Frontal cortex activation and reward
4. ORs in the Corticostriatal Circuit
4.1. OR Pharmacology and Toxicology
4.1.1. OR effects on cellular functions
4.1.2. Desensitization, tolerance, and receptor internalization
4.1.3. Opiate-related toxicity
4.2.1.1. Regional receptor expression data
4.2.1.2. Cellular receptor expression data
4.2.1.3. Electrophysiology data
4.2.1.4. Synthesis of cortical histological and electrophysiological data
4.2.2.1. Regional receptor expression data
4.2.2.2. Cellular receptor expression data
4.2.2.3. Electrophysiology data
4.2.2.4. Synthesis of striatal histological and electrophysiological data
5. Theoretical Actions of Idealized Opioid Agonists on the Corticostriatal Circuit
5.1. Acute Administration
5.2. Acute Desensitization, Tolerance, and Toxic Effects
6. Clinical Data on Cognitive Dysfunction and Mood Symptoms in People With OUD
6.1. Opioid Effects on Frontal Cortex-Dependent Cognitive Function
6.1.1. Evidence of impaired frontal cortex-dependent cognitive function after acute opioid administration
6.1.2. No evidence of long-term cognitive impairment in chronic pain patients under well-controlled courses of opioid tre ...
6.1.3. Evidence of impaired frontal cortex-dependent cognitive function in OUD patients
6.1.3.3. Risk and decision making
6.2. Evidence of Impaired Mood in OUD Patients
6.3. Evidence of Altered Frontal Cortex Biology in OUD Patients
6.3.1. PET, SPECT, and fMRI studies
6.3.2. Evidence of structural changes in OUD patients
6.4. Possible Causes of Reduced GMV
7. Conclusions and Recommendations
Chapter 6: Opioid modulation of depression: A focus on imaging studies
2. Imaging and Depression
2.1. Positron Emission Tomography: Preclinical Studies
2.2. Positron Emission Tomography: Clinical Studies
2.3. Magnetic Resonance Imaging: Preclinical Studies
2.4. Magnetic Resonance Imaging: Clinical Studies
3. Depression and the Opioid System
3.1. Preclinical Evidence of Opioid System Modulation of Depression
4. Depression, Imaging, and the Opioid System
4.1. Positive and Negative Affective States
The Opioid System as the Interface between the Brain’s Cognitive and Motivational Systems
( Volume 239 )
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
